MT1 receptor Inhibitors
2 drugsAbout MT1 receptor
The MT1 receptor, also known as Melatonin Receptor 1A, is a G protein-coupled receptor (GPCR) crucial in regulating the sleep-wake cycle and circadian rhythms. It mediates the effects of melatonin, influencing sleep propensity, hormone secretion, and other physiological processes.
The MT1 receptor is a therapeutic target for sleep disorders, evidenced by the approval of drugs like Rozerem (ramelteon). Currently, there is no genetic evidence data available linking the MT1 receptor to specific diseases.
Two small molecule drugs, Rozerem (Takeda) and Ramelteon (Aurobindo Pharma), target the MT1 receptor for sleep-related indications. These drugs were approved between 2005 and 2013, with Rozerem being the first.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Circadian Rhythm Disorders with only 1 trials.
Top MT1 receptor Drugs
The competitive landscape includes Aurobindo Pharma and Takeda, with approved drugs.
The market is concentrated among a few players, indicating potential entry barriers for new companies.
MT1 receptor Drug Modality Landscape
Modalities
Routes of Administration
MT1 receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
The exclusive use of small molecules suggests an opportunity to explore alternative modalities like biologics for novel therapeutic effects.
MT1 receptor Clinical Trials 28 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 4 | 3 | 1 | 0 | 75% |
| Phase 3 | 6 | 0 | 5 | 1 | 0% |
| Phase 4 | 15 | 9 | 4 | 2 | 69% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved MT1 receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting MT1 receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
MT1 receptor Drug Approval Timeline (2005 - 2022)
The approval timeline spans 9 years, with the first drug approved in 2005 and the most recent in 2013.
The limited approval activity in recent years suggests potential market saturation or challenges in developing new MT1 receptor-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 20 clinical trials targeting MT1 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities